my country's recombinant new crown virus vaccine (adenovirus vector) was approved by the State Food and Drug Administration for conditional approval for marketing registration application

Xinhua News Agency, Beijing, February 27 (Wang Yitao, Wang Di) The Chinese recombinant new coronavirus vaccine (adenovirus vector) developed by a team led by Chen Wei, an academician of the Chinese Academy of Engineering and a researcher at the Academy of Military Medicine of the Academy of Military Sciences, won the National Drug Supervision on the 25th.

The State Food and Drug Administration, in accordance with relevant regulations and in accordance with the special drug approval procedures, conducts emergency review and approval, conditionally approves the marketing registration application of recombinant new crown vaccine (adenovirus vector), requires continued research work, completes the conditional requirements, and timely Submit follow-up research results.

The recombinant new crown vaccine (adenovirus vector) adopts a single-dose immunization program, which can be stored stably between 2 and 8 degrees Celsius, and is easy to transport and store.

The vaccine has previously been authorized for emergency use in Pakistan and Mexico.